A newly released Advanced Therapy Medicinal Products Market analysis report by Future Market Insights shows that global sales of the Advanced Therapy Medicinal Products Market in 2021 were held at USD 8.7 billion. With a CAGR of 15% from 2022 to 2032, the market is projected to reach a valuation of USD 39 billion by 2032. Tissue Engineered Product segment is forecasted to be the most revenue-generating market between 2022 and 2032, which is projected to grow at a CAGR of 10.4% from 2022 to 2032.
| Attribute | Details |
|---|---|
| Global Advanced Therapy Medicinal Products Market (2022) | USD 9.8 Billion |
| Global Advanced Therapy Medicinal Products Market (2032) | USD 39 Billion |
| Global Advanced Therapy Medicinal Products Market CAGR (2022 to 2032) | 15% |
| USA Advanced Therapy Medicinal Products Market CAGR (2022 to 2032) | 15.9% |
| Key Companies Profiled | Spark Therapeutics, Inc.; Bluebird Bio, Inc.; Novartis AG; UniQure N.V.; Celgene Corporation; Gilead Lifesciences, Inc.; Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; MEDIPOST; Vericel Corporation; PHARMICELL Co., Ltd; Organogenesis Inc. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Advanced Therapy Medicinal Products Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2015 to 2021, the market value of the Advanced Therapy Medicinal Products Market increased at around 11.7% CAGR.
The introduction of Advanced Therapy Medicinal Products has changed the pharmaceutical sector and the landscape of disease treatment. It has paved the way for innovative treatments for incurable diseases and cancers of various types.
Although the market for advanced therapeutic pharmaceutical products is still in its infancy, it is steadily rising. Traditional medication producers looking for a competitive edge are considering ATMPs as a profitable source of revenue in future healthcare systems. This field is now quite busy, with corporations investing heavily in ATMP clinical trials following the approval of authorized drugs.
Increased cases of Alzheimer's disease around the world, increased demand for advanced gene therapies, increased prevalence of neurodegenerative diseases, increased geriatric population, and surged genetic disorders are driving the growth of the advanced therapy medicinal products market. Owing to these factors, the market is projected to reach a valuation of USD 39 billion by 2032.
According to recent sources, there is a lot of development effort in the ATMP industry, which doesn't seem to match the small number of ATMPs now in the European market. Despite the fact that over 500 clinical trials using ATMPs were conducted between 2009 and 2017, only 19 market authorization applications were submitted to the European Medicines Agency.
The consolidated marketing permission was given to ten ATMPs. Three of these corporations later revoked the license, and one stopped marketing the product, all for commercial reasons. To appropriately appraise the potential of ATMPs, a thorough understanding of stakeholder difficulties encountered during development is required.
ATMP's high cost makes it unaffordable for both public and private payers, limiting patient access to therapy for life-threatening disorders and diseases. Due to ATMP's limited utilization in ordinary clinical treatment, the majority of the issues in this sector are connected to trial implementation.
Surged investment to fund clinical trials has boosted the market of cell therapy in recent years. The institution of operational guidelines to assist cell therapy as well as the approval of sophisticated medicines have also aided the category's dominance.
The clearance of gene treatments in recent years has considerably expedited clinical trials in this field. Furthermore, Covid-19 opened new avenues for major players to invest in T-cell research to check viral infection. The research community is examining the possibilities of innovative medicines for COVID-19 patients, which will help the market flourish.
The United States' robust pipeline of Advanced Therapy Medicinal Products has propagated market revenue. In addition, corporations in the United States are moving their attention from traditional medication research to Advanced Therapy Medicinal Products, which is propelling regional growth.
Due to the developing Advanced Therapy Medicinal Products landscape in emerging economies such as China, the market in the Asia Pacific is likely to grow at the highest rate. The rise of the regional market has been fueled by the expansion of China-based CDMOs.
Principal Consultant
During the projected period, North America is expected to lead the global market for Advanced Therapy Medicinal Products with a CAGR of over 15%.
North America was the largest market for advanced therapy medicinal products with over 50% share in 2021. Investments in Research and Development and a favorable regulatory environment are the key dynamics for the large market for advanced therapy medicinal products in North America. In addition, the fast-growing number of clinical trials in this innovative therapeutic method in the United States contributes to regional growth.
In March 2021, the United States accounted for roughly 60% of all ongoing gene therapy clinical trials worldwide, which is expected to lead to the advanced therapy medicinal products market at USD 17.3 Billion by 2032. The market in the US is expected to grow at a CAGR of 15.9%.
The market in the UK is projected to reach a valuation of USD 1.2 Billion by 2032. Growing at a CAGR of 15.9% from 2022 to 2032, the market in the country is expected to gross an absolute dollar opportunity of USD 13.2 Billion.
In Japan, the market is expected to reach USD 1.4 Billion by 2032. With a CAGR of 15.3% during the forecast period, the market is projected to garner an absolute dollar opportunity of USD 1.1 Billion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tissue Engineered Product was the largest revenue-generating segment in the Advanced Therapy Medicinal Products Market in 2021, and it is expected to maintain its dominance during the forecast period, growing at a CAGR of 10.4%.
The incorporation of tissue-engineered procedures in treatments that need functional repair of any diseased or wounded area of the body can be linked to this dominance. The number of articles, research papers, translational products, and clinical trials, has increased significantly in the recent past.
Furthermore, the growth in revenue of tissue-engineered products is propelled by continual advancements in technology to encourage the tissue engineering process. For example, researchers at the University of Illinois in Chicago introduced a novel hydrogel-shaped-changing 4D material in February 2021. This material can change its shape in reaction to physiological stimuli.
On the other hand, the CAR-T treatment segment is gaining traction in the market and is predicted to grow at the quickest rate over the projection period. Novartis AG, for example, is concentrating on broadening the global reach of its CAR-T treatments. For instance, Health Sciences Authority recently authorized Kymriah as the first commercially licensed CAR-T therapy in Singapore.
The Advanced Therapy Medicinal Products market is highly consolidated. Some of the key players in the market are Spark Therapeutics, Inc., Bluebird Bio, Inc., Novartis AG, UniQure N.V., Celgene Corporation, Gilead Lifesciences, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, Vericel Corporation, PHARMICELL Co., Ltd, and Organogenesis Inc.
Some of the recent developments of key Advanced Therapy Medicinal Products providers are as follows:
Similarly, recent developments related to companies in the Advanced Therapy Medicinal Products Market have been tracked by the team at Future Market Insights, which are available in the full report.
The global Advanced Therapy Medicinal Products Market is worth more than USD 8.7 billion at present.
The value of the Advanced Therapy Medicinal Products Market is projected to increase at a CAGR of around 15% from 2022 to 2032.
Tissue Engineered Product segment is projected to maintain its dominance during the forecast period, growing at a CAGR of 10.4%.
The market in North America is expected to grow at a CAGR of 15.8% in the Advanced Therapy Medicinal Products market from 2022 to 2032.
Spark Therapeutics, Inc., Bluebird Bio, Inc., Novartis AG, UniQure N.V., and Celgene Corporation are the major companies operating in the Advanced Therapy Medicinal Products Market.
1. Executive Summary | Advanced Therapy Medicinal Products Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Therapy Type 5.1. Cell Therapy 5.1.1. Stem Cell Therapy 5.1.2. Non-stem Cell Therapy 5.2. CAR-T Therapy 5.3. Gene Therapy 5.4. Tissue Engineered Product 6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 6.1. North America 6.2. Latin America 6.3. Europe 6.4. Asia Pacific 6.5. Middle East and Africa (MEA) 7. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 8. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 9. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 10. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 11. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 12. Key Countries Market Analysis 13. Market Structure Analysis 14. Competition Analysis 14.1. Spark Therapeutics, Inc. 14.2. Bluebird Bio, Inc. 14.3. Novartis AG 14.4. UniQure N.V. 14.5. Celgene Corporation 14.6. Gilead Lifesciences, Inc. 14.7. Kolon TissueGene, Inc. 14.8. JCR Pharmaceuticals Co., Ltd. 14.9. MEDIPOST 14.10. Vericel Corporation 14.11. PHARMICELL Co., Ltd 14.12. Organogenesis Inc. 15. Assumptions & Acronyms Used 16. Research Methodology
Explore Healthcare Insights
View Reports
Advanced Therapy Medicinal Products Market
